194 related articles for article (PubMed ID: 30643974)
21. Can pelvic node dissection at radical prostatectomy influence the nodal recurrence at salvage lymphadenectomy for prostate cancer?
Sivaraman A; Benfante N; Touijer K; Coleman J; Scardino P; Laudone V; Eastham J
Investig Clin Urol; 2018 Mar; 59(2):83-90. PubMed ID: 29520383
[TBL] [Abstract][Full Text] [Related]
22. Defining the optimal template of salvage lymph node dissection for unilateral pelvic nodal recurrence of prostate cancer following radical prostatectomy.
Van Eecke H; Devos G; Vansevenant B; Vander Stichele A; Devlies W; Berghen C; Everaerts W; De Meerleer G; Joniau S
Int J Urol; 2023 Jan; 30(1):92-99. PubMed ID: 36305586
[TBL] [Abstract][Full Text] [Related]
23. Salvage Pelvic Lymph Node Dissection and Current State of Imaging for Recurrent Prostate Cancer: Does a Standard Exist?
McCloskey H; Jacobs J; Zambrano I; Moore T; Khandani AH; Bjurlin MA
Curr Urol Rep; 2020 Nov; 21(12):62. PubMed ID: 33159608
[TBL] [Abstract][Full Text] [Related]
24. Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy.
Bravi CA; Droghetti M; Fossati N; Gandaglia G; Suardi N; Mazzone E; Cucchiara V; Scuderi S; Barletta F; Schiavina R; Osmonov D; Juenemann KP; Boeri L; Karnes RJ; Kretschmer A; Buchner A; Stief C; Hiester A; Nini A; Albers P; Devos G; Joniau S; Van Poppel H; Grubmüller B; Shariat SF; Heidenreich A; Pfister D; Tilki D; Graefen M; Gill IS; Mottrie A; Karakiewicz PI; Montorsi F; Briganti A
Eur Urol Oncol; 2022 Jun; 5(3):285-295. PubMed ID: 34176768
[TBL] [Abstract][Full Text] [Related]
25. Metastases-yield and Prostate-specific Antigen Kinetics Following Salvage Lymph Node Dissection for Prostate Cancer: A Comparison Between Conventional Surgical Approach and Prostate-specific Membrane Antigen-radioguided Surgery.
Knipper S; Tilki D; Mansholt J; Berliner C; Bernreuther C; Steuber T; Maurer T; Graefen M
Eur Urol Focus; 2019 Jan; 5(1):50-53. PubMed ID: 30292421
[TBL] [Abstract][Full Text] [Related]
26. De novo neurogenic bladder dysfunction after salvage lymph node dissection in patients with nodal recurrence of prostate cancer.
Hanske J; Müller G; van Ophoven A; von Landenberg N; Roghmann F; Palisaar RJ; von Bodman C; Noldus J; Brock M
Neurourol Urodyn; 2018 Aug; 37(6):1988-1995. PubMed ID: 29504654
[TBL] [Abstract][Full Text] [Related]
27. Value of
Rauscher I; Düwel C; Wirtz M; Schottelius M; Wester HJ; Schwamborn K; Haller B; Schwaiger M; Gschwend JE; Eiber M; Maurer T
BJU Int; 2017 Jul; 120(1):40-47. PubMed ID: 27862863
[TBL] [Abstract][Full Text] [Related]
28. Management of positive lymph nodes following radical prostatectomy.
Heidenreich A; Rieke M; Mahjoub S; Pfister D
Arch Esp Urol; 2019 Mar; 72(2):182-191. PubMed ID: 30855020
[TBL] [Abstract][Full Text] [Related]
29. (11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series.
Graziani T; Ceci F; Castellucci P; Polverari G; Lima GM; Lodi F; Morganti AG; Ardizzoni A; Schiavina R; Fanti S
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1971-9. PubMed ID: 27277279
[TBL] [Abstract][Full Text] [Related]
30. Contemporary role of salvage lymphadenectomy in patients with recurrence following radical prostatectomy.
Abdollah F; Briganti A; Montorsi F; Stenzl A; Stief C; Tombal B; Van Poppel H; Touijer K
Eur Urol; 2015 May; 67(5):839-49. PubMed ID: 24698524
[TBL] [Abstract][Full Text] [Related]
31. Event-free survival after
Ceci F; Rovera G; Iorio GC; Guarneri A; Chiofalo V; Passera R; Oderda M; Dall'Armellina S; Liberini V; Grimaldi S; Bellò M; Gontero P; Ricardi U; Deandreis D
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(9):3257-3268. PubMed ID: 35217883
[TBL] [Abstract][Full Text] [Related]
32. [Salvage lymph node dissection for nodal recurrent prostate cancer].
Stolzenbach LF; Knipper S; Maurer T
Aktuelle Urol; 2020 Jun; 51(3):258-264. PubMed ID: 32219775
[TBL] [Abstract][Full Text] [Related]
33. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
34. Toxicity and efficacy of salvage carbon 11-choline positron emission tomography/computed tomography-guided radiation therapy in patients with lymph node recurrence of prostate cancer.
Fodor A; Berardi G; Fiorino C; Picchio M; Busnardo E; Kirienko M; Incerti E; Dell'Oca I; Cozzarini C; Mangili P; Pasetti M; Calandrino R; Gianolli L; Di Muzio NG
BJU Int; 2017 Mar; 119(3):406-413. PubMed ID: 27104782
[TBL] [Abstract][Full Text] [Related]
35. Salvage lymph node dissection after
Herlemann A; Kretschmer A; Buchner A; Karl A; Tritschler S; El-Malazi L; Fendler WP; Wenter V; Ilhan H; Bartenstein P; Stief CG; Gratzke C
Oncotarget; 2017 Oct; 8(48):84180-84192. PubMed ID: 29137414
[TBL] [Abstract][Full Text] [Related]
36. Nodal Oligorecurrent Prostate Cancer: Anatomic Pattern of Possible Treatment Failure in Relation to Elective Surgical and Radiotherapy Treatment Templates.
De Bruycker A; De Bleser E; Decaestecker K; Fonteyne V; Lumen N; De Visschere P; De Man K; Delrue L; Lambert B; Ost P
Eur Urol; 2019 May; 75(5):826-833. PubMed ID: 30503072
[TBL] [Abstract][Full Text] [Related]
37. Cohort Study of Oligorecurrent Prostate Cancer Patients: Oncological Outcomes of Patients Treated with Salvage Lymph Node Dissection via Prostate-specific Membrane Antigen-radioguided Surgery.
Knipper S; Mehdi Irai M; Simon R; Koehler D; Rauscher I; Eiber M; van Leeuwen FWB; van Leeuwen P; de Barros H; van der Poel H; Budäus L; Steuber T; Graefen M; Tennstedt P; Heck MM; Horn T; Maurer T
Eur Urol; 2023 Jan; 83(1):62-69. PubMed ID: 35718637
[TBL] [Abstract][Full Text] [Related]
38. Salvage pelvic lymph node dissection in recurrent prostate cancer: surgical and early oncological outcome.
Claeys T; Van Praet C; Lumen N; Ost P; Fonteyne V; De Meerleer G; Lambert B; Delrue L; De Visschere P; Villeirs G; Decaestecker K
Biomed Res Int; 2015; 2015():198543. PubMed ID: 25695051
[TBL] [Abstract][Full Text] [Related]
39. Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study.
Steuber T; Jilg C; Tennstedt P; De Bruycker A; Tilki D; Decaestecker K; Zilli T; Jereczek-Fossa BA; Wetterauer U; Grosu AL; Schultze-Seemann W; Heinzer H; Graefen M; Morlacco A; Karnes RJ; Ost P
Eur Urol Focus; 2019 Nov; 5(6):1007-1013. PubMed ID: 29530632
[TBL] [Abstract][Full Text] [Related]
40. Robot-assisted Salvage Lymph Node Dissection for Clinically Recurrent Prostate Cancer.
Montorsi F; Gandaglia G; Fossati N; Suardi N; Pultrone C; De Groote R; Dovey Z; Umari P; Gallina A; Briganti A; Mottrie A
Eur Urol; 2017 Sep; 72(3):432-438. PubMed ID: 27600589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
